Demyelinating and Inflammatory Diseases
- Age at Relapsing-Remitting Multiple Sclerosis Onset Increases in Over 50 Years
- Ublituximab vs Teriflunomide for Reducing Relapses in Multiple Sclerosis
- Tumefactive Demyelinating Lesions, Sentinel Lesions of PCNSL Compared
- Hippotherapy Simulation for Multiple Sclerosis Helps Mobility, Muscle Strength
- Inflammation May Be Interventional Target in Primary Progressive Multiple Sclerosis
- Ublituximab Bests Teriflunomide in Relapsing Multiple Sclerosis
- High Intake of Ultra-Processed Foods Associated With Dementia Risk
- Medication Error Possible if Incompatible Autoinjector Used to Administer MS Drug
- Retinal Layer Thinning May Predict Relapse Remission in Multiple Sclerosis
- Psychotherapeutic Interventions Improve Emotional Competencies in MS
- Risk Factors Identified for Poor Health-Related Quality of Life in Patients With Multiple Sclerosis
- Multiple Sclerosis Disease Activity in Patients Not Exacerbated by COVID-19
Conference Coverage
MORE MEETINGS
Clinical Tools
Powered by
Powered by 
MORE CLINICAL TOOLS
